{
    "id": 26862,
    "fullName": "NECTIN4 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "NECTIN4 over exp indicates an over expression of the Nectin4 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 81607,
        "geneSymbol": "NECTIN4",
        "terms": [
            "NECTIN4",
            "EDSS1",
            "LNIR",
            "nectin-4",
            "PRR4",
            "PVRL4"
        ]
    },
    "variant": "over exp",
    "createDate": "08/07/2017",
    "updateDate": "08/07/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11651,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with Enfortumab vedotin resulted in an overall response rate of 40% (n=60), with 3 complete responses, a median duration of response of 18 weeks, and median progression-free survival of 17 weeks in patients with metastatic urothelial carcinoma demonstrating high Nectin4 expression (J Clin Oncol 35, 2017 (suppl; abstr 106); NCT02091999).",
            "molecularProfile": {
                "id": 28178,
                "profileName": "NECTIN4 over exp"
            },
            "therapy": {
                "id": 4125,
                "therapyName": "Enfortumab vedotin-ejfv",
                "synonyms": null
            },
            "indication": {
                "id": 2671,
                "name": "transitional cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9687,
                    "pubMedId": null,
                    "title": "A Phase I Study of Enfortumab Vedotin: Updated Analysis of Patients with Metastatic Urothelial Cancer.",
                    "url": "http://meetinglibrary.asco.org/record/152459/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28178,
            "profileName": "NECTIN4 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}